The US Food and Drug Administration (USFDA) has provided its final approval to the drug firm Zydus Cadila for marketing oxybutynin chloride tablets that are used in treating symptoms of overactive bladder and urinary incontinence.

The company has said in a BSE filing that it “has received the final approval from the USFDA to market oxybutynin chloride extended release tablets in the strength of 5 mg, 10 mg, 15 mg.”

Read EquityPandit’s Technical Analysis on Nifty Pharma